ERBB4 and neoplasm: Researchers suggested that increased ERBB4 signalling, oestrogen signalling loss, responsive states, JNK pathway activation, and increase in basal-like tumour attribute as underlying features for developing endocrine therapy resistance and can be potential biomarkers while selecting and treating early-stage breast cancer patients[15].